Pharmacy-refill measure of adherence to efavirenz can predict maintenance of HIV viral suppression

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 20, Issue 6, 2008, Pages 741-745

  Saberi, P ^a   Caswell, N ^b   Amodio Groton, M ^c   Alpert, P ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Montefiore Medical Center ^*

^c MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Adherence; Efavirenz; Pharmacy; Refill

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

DRUG HALF LIFE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NONHUMAN; PATIENT COMPLIANCE; PHARMACY; PILL; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; REPEATED DRUG DOSE; RETROSPECTIVE STUDY; REVIEW; VIRUS LOAD;

BENZOXAZINES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MEDICATION ADHERENCE; PHARMACY SERVICE, HOSPITAL; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 46249084594     PISSN: 09540121     EISSN: 13600451     Source Type: Journal    
DOI: 10.1080/09540120701694006     Document Type: Review

References (6)

1. Bangsberg, D. (2006). Less than 95% adherence to non-nucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clinical Infectious Diseases, 43, 939-941.
2. Bristol-Myers Squibb Company (2005). Sustiva (efavirenz) product information. Princeton, NJ: Author.
3. Grossberg, R., Zhang, Y., & Gross, R. (2004). A time-to-prescription- refill measure of antiretroviral adherence predicted changes in viral load in HIV. Journal of Clinical Epidemiology, 57, 1107-1110.
4. Department of Health and Human Services (2008). Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29, 2008; 1-128. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed Feb 2008.
5. Maggiolo, F., Ravasio, L., Diego, R., et al. (2005). Similar adherence rates favor different virologic outcomes for patients treated with non-nucleoside analogues or protease inhibitors. Clinical Infectious Diseases, 40, 158-163.
6. Paterson, D.L., Swindells, S., Mohr, J., et al. (2000). Adherence to protease inhibitor therapy and outcome in patients with HIV infection. Annals of Internal Medicine, 133, 21-30.